Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians.
Kähler KC, Blome C, Forschner A, Gutzmer R, Hauschild A, Heinzerling L, Livingstone E, Loquai C, Müller-Brenne T, Schadendorf D, Utikal J, Wagner T, Augustin M. Kähler KC, et al. Among authors: schadendorf d. Oncotarget. 2018 May 25;9(40):26217-26225. doi: 10.18632/oncotarget.25439. eCollection 2018 May 25. Oncotarget. 2018. PMID: 29899854 Free PMC article.
Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis.
Hauschild A, Weichenthal M, Balda BR, Becker JC, Wolff HH, Tilgen W, Schulte KW, Ring J, Schadendorf D, Lischner S, Burg G, Dummer R. Hauschild A, et al. Among authors: schadendorf d. J Clin Oncol. 2003 Aug 1;21(15):2883-8. doi: 10.1200/JCO.2003.07.116. J Clin Oncol. 2003. PMID: 12885805 Clinical Trial.
Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG).
Zimpfer-Rechner C, Hofmann U, Figl R, Becker JC, Trefzer U, Keller I, Hauschild A, Schadendorf D. Zimpfer-Rechner C, et al. Among authors: schadendorf d. Melanoma Res. 2003 Oct;13(5):531-6. doi: 10.1097/00008390-200310000-00012. Melanoma Res. 2003. PMID: 14512795 Clinical Trial.
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial.
Hauschild A, Weichenthal M, Rass K, Linse R, Berking C, Böttjer J, Vogt T, Spieth K, Eigentler T, Brockmeyer NH, Stein A, Näher H, Schadendorf D, Mohr P, Kaatz M, Tronnier M, Hein R, Schuler G, Egberts F, Garbe C. Hauschild A, et al. Among authors: schadendorf d. J Clin Oncol. 2010 Feb 10;28(5):841-6. doi: 10.1200/JCO.2009.23.1704. Epub 2010 Jan 4. J Clin Oncol. 2010. PMID: 20048184 Clinical Trial.
PLX4032: does it keep its promise for metastatic melanoma treatment?
Livingstone E, Zimmer L, Piel S, Schadendorf D. Livingstone E, et al. Among authors: schadendorf d. Expert Opin Investig Drugs. 2010 Nov;19(11):1439-49. doi: 10.1517/13543784.2010.527945. Epub 2010 Oct 14. Expert Opin Investig Drugs. 2010. PMID: 20942773 Review.
[Forward].
Hauschild A, Kölbl O, Mackensen A, Schadendorf D. Hauschild A, et al. Among authors: schadendorf d. Onkologie. 2011;34 Suppl 2:1. doi: 10.1159/000324821. Onkologie. 2011. PMID: 21447984 Free article. German. No abstract available.
Current advances and perspectives in the treatment of advanced melanoma.
Livingstone E, Zimmer L, Vaubel J, Schadendorf D. Livingstone E, et al. Among authors: schadendorf d. J Dtsch Dermatol Ges. 2012 May;10(5):319-25. doi: 10.1111/j.1610-0387.2012.07895.x. Epub 2012 Mar 20. J Dtsch Dermatol Ges. 2012. PMID: 22432863 Free article. Review.
1,114 results